Joshua B. Cohen - Nov 16, 2023 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role: Co-Chief Executive Officer, Director
Signature: /s/ Justin Klee, as Attorney in Fact
Stock symbol: AMLX
Transactions as of: Nov 16, 2023
Transactions value $: $100,000
Form type: 4
Date filed: 11/20/2023, 08:20 PM
Previous filing: Mar 20, 2023
Next filing: Jan 11, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMLX	Common Stock	Options Exercise	$100K	+63.7K	+2.24%	$1.57^*	2.91M	Nov 16, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMLX	Stock Option (Right to Buy)	Options Exercise	$0	-63.7K	-63.69%	$0.00	36.3K	Nov 16, 2023	Common Stock	63.7K	$1.57	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25,012 shares subject to such option vested and became exercisable on February 26, 2021, with the remaining shares vesting in monthly installments of 2,083 shares thereafter.

Remarks:

Exhibit List: Exhibit 24. This Power of Attorney was inadvertently omitted from the Form 3 filed on January 6, 2022.